Evodenovo, Inc.
Publicly observedandover, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | andover | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Evodenovo, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | L17ZDJF2LJH1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Apr 2022Publicly observed
NIH SBIR/STTR award: Development of small molecule therapeutics for mitigating opioid withdrawal syndrome
USD 687,310.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
- Grant15 Apr 2022Publicly observed
NIH SBIR/STTR award: Development of small molecule therapeutics for mitigating opioid withdrawal syndrome
USD 1,094,320.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.